drugset / Trial / NCT02462473
A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the number of Medication Treatment Modifications (MTMs) made by the clinician at every visit when antipsychotic medication plasma levels (AMPL) results are available compared to when AMPL results are not available.
Timeline
- Start
- 2015-05
- Primary completion
- 2016-01
- Completion
- 2016-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aripiprazole | Other / unclassified | 5 mg | Oral |
| Subject | Olanzapine | Small molecule | 5 mg | Oral |
| Subject | Paliperidone | Unknown | 3 mg | Oral |
| Subject | Paliperidone | Unknown | 39 mg | Oral |
| Subject | Quetiapine | Small molecule | 150 mg | Oral |
| Subject | Risperidone | Other / unclassified | 1 mg | Oral |
| Subject | Risperidone | Other / unclassified | 12.5 mg | Oral |